{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:37:06Z","timestamp":1786700226229,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Germline EGFR pathogenic variants (PVs) are rare and define a distinct hereditary subset of NSCLC with unique clinical characteristics. Germline EGFR p.T790M is the most frequent and best characterized, with reported sensitivity to first- and second-generation EGFR-TKIs. Yet, the response of germline EGFR variants, especially the rarer ones such as p.V843I, to osimertinib remains poorly characterized. Given the very low frequency of germline non-p.T790M variants, their clinical relevance can only be investigated via case reports. Herein, we report what is, to the best of our knowledge, the first case of advanced lung adenocarcinoma harboring a germline EGFR p.V843I variant coexisting in cis with the unusual somatic EGFR exon 19 C-helix deletion, p.S752_I759del. Additionally, a somatic TP53 variant was detected. Treatment with afatinib induced a partial response lasting only six months, as rapid disease progression occurred without identifiable acquired resistance mechanisms. Subsequently, no objective response to osimertinib or afatinib rechallenge was observed. Acquired EGFR and MET amplification were detected in corresponding rebiopsies. Overall survival was 29 months. Our findings suggest that, despite the presence of the previously reported EGFR-TKI-sensitive, EGFR p.S752_I759del, the co-occurrence of germline p.V843I may have contributed to reduced sensitivity to afatinib and osimertinib. This case expands the molecular spectrum of hereditary EGFR-mutated NSCLC and, together with our narrative review of the literature, supports an emerging model in which germline EGFR PVs may act both as tumor-predisposing events and as potential mechanisms of early resistance to EGFR-TKIs.<\/jats:p>","DOI":"10.3390\/ijms27167260","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:04:01Z","timestamp":1786698241000},"page":"7260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs"],"prefix":"10.3390","volume":"27","author":[{"given":"Katarina","family":"Resen","sequence":"first","affiliation":[{"name":"Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linea Cecilie","family":"Melchior","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-0178","authenticated-orcid":false,"given":"Jens Benn","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-6798","authenticated-orcid":false,"given":"Karin Anna Wallentin","family":"Wadt","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"},{"name":"Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-9346","authenticated-orcid":false,"given":"Edyta Maria","family":"Urbanska","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-3535","authenticated-orcid":false,"given":"Eric","family":"Santoni-Rugiu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, M., Niu, X., Liu, H., and Chen, J. (2023). Germline EGFR Mutations in Lung Cancer (Review). Oncol. Lett., 26.","DOI":"10.3892\/ol.2023.13868"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jtho.2024.06.004","article-title":"Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations","volume":"19","author":"Pan","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtho.2024.07.007","article-title":"Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening","volume":"19","author":"Pujol","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide Frequency of Commonly Detected EGFR Mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","first-page":"2892","article-title":"EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (MutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/ng1671","article-title":"Inherited Susceptibility to Lung Cancer May Be Associated with the T790M Drug Resistance Mutation in EGFR","volume":"37","author":"Bell","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1078-0432.CCR-09-2437","article-title":"Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report","volume":"16","author":"Girard","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0b013e318250ed9d","article-title":"Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping","volume":"7","author":"Oxnard","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/JTO.0000000000000130","article-title":"Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations","volume":"9","author":"Gazdar","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10689-015-9796-x","article-title":"Germline Mutations Predisposing to Non-Small Cell Lung Cancer","volume":"14","author":"Clamon","year":"2015","journal-title":"Fam. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited Lung Cancer Syndromes Targeting Never Smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JTO.0b013e3181915f92","article-title":"Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer","volume":"4","author":"Prudkin","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/JTO.0000000000000052","article-title":"Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort","volume":"9","author":"Yu","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.21037\/tlcr-20-1001","article-title":"Presentation of EGFR Mutations in 162 Family Probands with Multiple Primary Lung Cancer","volume":"10","author":"Li","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1200\/JCO.23.01372","article-title":"Germline EGFR Mutations and Familial Lung Cancer","volume":"41","author":"Oxnard","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, T., Zheng, Q., Deng, C., Li, X., Huang, J., Fan, J., Huang, B., Zhang, J., Chang, X., and Nie, X. (2024). Identification of EGFR R776H Germline Mutations in a Patient with Multifocal Lung Adenocarcinoma: A Case Report and Literature Review. Respir. Med. Case Rep., 50.","DOI":"10.1016\/j.rmcr.2024.102051"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1183\/09059180.00009313","article-title":"Germ-Line Exon 21 EGFR Mutations, V843I and P848L, in Nonsmall Cell Lung Cancer Patients","volume":"23","author":"Prim","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1200\/JCO.2012.42.1586","article-title":"Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated with Lung Cancer with Squamous Differentiation","volume":"31","author":"Kunst","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtho.2018.12.006","article-title":"EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","volume":"14","author":"Lu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.resinv.2018.12.005","article-title":"Germline Mutations in Lung Cancer","volume":"57","author":"Shukuya","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.athoracsur.2007.10.012","article-title":"Novel Germline Mutation: EGFR V843I in Patient with Multiple Lung Adenocarcinomas and Family Members with Lung Cancer","volume":"85","author":"Ikeda","year":"2008","journal-title":"Ann. Thorac. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1200\/JCO.2010.31.4492","article-title":"Familial Lung Adenocarcinoma Caused by the EGFR V843I Germ-Line Mutation","volume":"29","author":"Ohtsuka","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2012.11.013","article-title":"A Dramatic Lung Cancer Course in a Patient with a Rare EGFR Germline Mutation Exon 21 V843I: Is EGFR TKI Resistance Predictable?","volume":"80","author":"Demierre","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/JTO.0000000000000241","article-title":"V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"9","author":"Matsushima","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ohtsuka, K., Ohnishi, H., Fujiwara, M., Morii, T., Matsushima, S., Ogura, W., Yamasaki, S., Kishino, T., Tanaka, R., and Watanabe, T. (2019). Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation. JCO Precis. Oncol., 3.","DOI":"10.1200\/PO.19.00104"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alsaddah, S., Papadakis, A.I., Wong, N., Palma, L., Szlachtycz, D., Cruz Marino, T., Fiset, P.-O., and Foulkes, W.D. (2023). Germline EGFR c.2527G > A (p.V843I) Variant and Familial Lung Cancer. Lung Cancer, 181.","DOI":"10.1016\/j.lungcan.2023.107247"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1634\/theoncologist.2019-0938","article-title":"Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation","volume":"25","author":"Huo","year":"2020","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2020.09.019","article-title":"Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation","volume":"150","author":"Song","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Liu, B., Qin, J., Yin, Y., Zhai, L., Liu, G., Lizaso, A., and Shi, D. (2021). The Emergence of Various Genetic Alterations Mediated the Osimertinib Resistance of a Patient Harboring Heterozygous Germline EGFR T790M: A Case Report. Ann. Transl. Med., 9.","DOI":"10.21037\/atm-20-7626"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.21037\/tlcr.2020.03.35","article-title":"EGFR Mutation Genotypes Affect Efficacy and Resistance Mechanisms of Osimertinib in T790M-Positive NSCLC Patients","volume":"9","author":"Zheng","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Santoni-Rugiu, E., Melchior, L.C., Urbanska, E.M., Jakobsen, J.N., de Stricker, K., Grauslund, M., and S\u00f8rensen, J.B. (2019). Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 11.","DOI":"10.3390\/cancers11070923"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Xu, C., Lei, L., Wang, W., Lin, L., Zhu, Y., Wang, H., Miao, L., Wang, L., Zhuang, W., and Fang, M. (2020). Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non\u2013Small Cell Lung Cancer and Response to EGFR TKIs. Transl. Oncol., 13.","DOI":"10.1016\/j.tranon.2020.100791"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: A Curated Database of Somatic Variants and Clinical Data for Cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26195","DOI":"10.18632\/oncotarget.25490","article-title":"Concomitant Driver Mutations in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer and Their Impact on Erlotinib Treatment","volume":"9","author":"Jakobsen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shimamura, S.S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., and Shibayama, R. (2022). Survival Past Five Years with Advanced, EGFR-Mutated or ALK-Rearranged Non-Small Cell Lung Cancer\u2014Is There a \u201cTail Plateau\u201d in the Survival Curve of These Patients?. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09421-7"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tokudome, N., Koh, Y., Akamatsu, H., Fujimoto, D., Okamoto, I., Nakagawa, K., Hida, T., Imamura, F., Morita, S., and Yamamoto, N. (2020). Differential Significance of Molecular Subtypes Which Were Classified into EGFR Exon 19 Deletion on the First Line Afatinib Monotherapy. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6593-1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zheng, C., Li, X., Ren, Y., Yin, Z., and Zhou, B. (2020). Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated with COMP and ITGB8 Upregulation and Poor Prognosis. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00030"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mhanna, L., Guibert, N., Milia, J., and Mazieres, J. (2019). When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. Curr. Treat. Options Oncol., 20.","DOI":"10.1007\/s11864-019-0652-3"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtho.2023.11.009","article-title":"Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC","volume":"19","author":"Le","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Le, X., Molife, C., Leusch, M.S., Rizzo, M.T., Peterson, P.M., Caria, N., Chen, Y., Gugel, E.G., and Visseren-Grul, C. (2022). TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Cancers, 14.","DOI":"10.3390\/cancers14246127"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","article-title":"Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated with Worse Outcomes in Patients with EGFR-Mutant Lung Cancer","volume":"19","author":"Stockhammer","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cllc.2025.04.007","article-title":"Distinct Role of TP53 Co-Mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer","volume":"26","author":"Wei","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum. Mutat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational Processes Shape the Landscape of TP53 Mutations in Human Cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/cas.16428","article-title":"Persist or Resist: Immune Checkpoint Inhibitors in EGFR-mutated NSCLC","volume":"116","author":"Zhu","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yang, J., Li, H., Li, B., Li, W., Guo, Q., Hu, L., Song, Z., and Zhou, B. (2021). Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.647598"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00019","article-title":"Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated with Multiple Lung Adenocarcinomas","volume":"1","author":"Hellmann","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Centeno, I., Blay, P., Santamar\u00eda, I., Astudillo, A., Pitiot, A.S., Osorio, F.G., Gonz\u00e1lez-Arriaga, P., Iglesias, F., Men\u00e9ndez, P., and Tard\u00f3n, A. (2011). Germ-Line Mutations in Epidermal Growth Factor Receptor (EGFR) Are Rare but May Contribute to Oncogenesis: A Novel Germ-Line Mutation in EGFR Detected in a Patient with Lung Adenocarcinoma. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-172"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/OTT.S391766","article-title":"A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review","volume":"16","author":"Li","year":"2023","journal-title":"Onco. Targets. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.6004\/jnccn.2017.7014","article-title":"EGFR -Mutant Non\u2013Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing","volume":"15","author":"Sukari","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/JTO.0b013e3182059a6f","article-title":"Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Patients","volume":"6","author":"Tibaldi","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, G., Zheng, Z., Wen, W., Zhao, H., Liu, X., Xie, J., and Han, L. (2024). Benefits of Osimertinib Treat a Lung Adenocarcinoma Patient with Germline EGFR T790M, Somatic EGFR 19-Del, TP53 and PIK3CA Mutations. Hered. Cancer Clin. Pract., 22.","DOI":"10.1186\/s13053-024-00286-4"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.cllc.2015.11.003","article-title":"Germline Mutation of T790M and Dual\/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma","volume":"17","author":"Lou","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jtho.2017.09.1963","article-title":"First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC","volume":"13","author":"Friedland","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jtho.2017.09.1962","article-title":"Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and\/or Liquid Biopsy","volume":"13","author":"Shukuya","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"M\u00e4kinen, N., Zhou, M., Bemus, M., Nevin, J., Nag, A., Chen, R., Colson, Y.L., Thorner, A.R., Oxnard, G.R., and Meyerson, M. (2021). Genomic Evolution in a Patient with Lung Adenocarcinoma with a Germline EGFR T790M Mutation. JTO Clin. Res. Rep., 2.","DOI":"10.1016\/j.jtocrr.2021.100146"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cai, D., Lou, J., Zhu, Y., and Wang, Y. (2026). Germ-Line Exon 21 EGFR V831H Mutation in Advanced NSCLC Resistance to Almonertinib: A Case Report. Front. Oncol., 16, Erratum in Front. Oncol.\u00a02026, 16, 1836262.","DOI":"10.3389\/fonc.2026.1758636"},{"key":"ref_61","first-page":"1","article-title":"Novel EGFR V834L Germline Mutation Associated with Familial Lung Adenocarcinoma","volume":"2","author":"Wagner","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10147-013-0602-1","article-title":"Rare and Complex Mutations of Epidermal Growth Factor Receptor, and Efficacy of Tyrosine Kinase Inhibitor in Patients with Non-Small Cell Lung Cancer","volume":"19","author":"Keam","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Saridaki, Z., Fountzilas, E., Alexopoulos, A., and Karachaliou, N. (2025). Inherited Rare Epidermal Growth Factor Receptor Mutation and Somatic Mutations in Patients with Non-Small Cell Lung Cancer: A Case Report. BMC Med. Genom., 18.","DOI":"10.1186\/s12920-025-02113-8"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Li, N., Liu, C., Xiong, L., Huang, D., and Jiang, Y. (2022). Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer. Ann. Transl. Med., 10.","DOI":"10.21203\/rs.3.rs-586793\/v1"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rossing, H.H., Grauslund, M., Urbanska, E.M., Melchior, L.C., Rask, C.K., Costa, J.C., Skov, B.G., S\u00f8rensen, J.B., and Santoni-Rugiu, E. (2013). Concomitant Occurrence of EGFR (Epidermal Growth Factor Receptor) and KRAS (V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog) Mutations in an ALK (Anaplastic Lymphoma Kinase)-Positive Lung Adenocarcinoma Patient with Acquired Resistance to Crizotinib: A Case Report. BMC Res. Notes, 6.","DOI":"10.1186\/1756-0500-6-489"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Urbanska, E.M., S\u00f8rensen, J.B., Melchior, L.C., Costa, J.C., and Santoni-Rugiu, E. (2020). Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082847"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:08:09Z","timestamp":1786698489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":66,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167260"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167260","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}